World hypertension day 2007

Hypertension

Volumn 49, Issue 5, 2007, Pages 939-940

  Jones, Daniel W ^a,b   Hall, John E ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TORCETRAPIB; VACCINE; CHOLESTEROL ESTER TRANSFER PROTEIN; HYPOCHOLESTEROLEMIC AGENT; QUINOLINE DERIVATIVE;

CARDIOVASCULAR RISK; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG COST; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; HUMAN; HYPERTENSION; INFECTION; KIDNEY DISEASE; LIPID BLOOD LEVEL; MEDICAL RESEARCH; PATIENT CARE; PRIORITY JOURNAL; RISK FACTOR; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DRUG ANTAGONISM; DRUG EFFECT; HEALTH; MORTALITY; PATHOPHYSIOLOGY;

ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; HUMANS; HYPERTENSION; QUINOLINES; RISK FACTORS; WORLD HEALTH;

EID: 34247877575     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.088740     Document Type: Editorial

References (16)

1. World Hypertension League Calendar. World Hypertension League. Available at: http://www.worldhypertensionleague.org/Pages/Calendar.aspx. Accessed March 26, 2007.
2. McKenney JM, Davidson MH, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin [see comment]. J Am Coll Cardiol. 2006;48:1782-1790.
3. US Food and Drug Administration. FDA statement: Pfizer stops all torcetrapib clinical trials in interest of patient safety. US Food and Drug Administration. 2006. Available at: http://www.fda.gov/bbs/topics/NEWS/2006/ NEW01514.html. Accessed March 26, 2007.
4. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
5. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Blood pressure lowering treatment trialists' collaboration. Lancet. 2000;356:1955-1964.
6. Turner R, Homan R, Stratton I, Cull C, Frighi V, Manley S, Matthews D, Neil A, McElroy H, Kohner E, Fox C, Hadden D, Wright D on behalf of the UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
7. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy [see comment]. Hypertension. 2001;38:E28-E32.
8. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
9. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Pobstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L. Bettencourt J, Walsh SM on behalf of the ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens. 2002;4:393-404.
10. British Heart Foundation Health Promotion Research Group. European Cardiovascular Disease Statistics. London, United Kingdom: British Heart Foundation and the European Heart Network; 2005.
11. Kearney PM, Welton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-223.
12. World Health Organization. The World Health Report 2002. Reducing Risks, Promoting Healthy Life. Geneva, Switzerland: World Health Organization; 2002.
13. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension. 2004;44:398-404.
14. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ, and the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
15. Lenfant C, Chobanian AV, Jones DW, Roccella EJ. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7): resetting the hypertension sails. Hypertension. 2003;41:1178-1179.
16. Meissner I, Whisnant JP, Sheps SG, Schwartz GL, O'Fallon WM, Covalt JL, Sicks JD, Bailey KR, Wiebers DO. Detection and control of high blood pressure in the community: do we need a wake-up call? Hypertension. 1999;34:466-471.